Pharmaceutical product placements integrate brands into story lines and may be an evolution in the industry's focus on direct-to-consumer advertising. Although it is still uncommon, the potential for such marketing is present and warrants attention. Medications have a unique status as a product category, and policies need to be tailored accordingly.
AdelsteinJonathan S. (2005), “Remarks of Jonathan S. Adelstein Commissioner, Federal Communications Commission: A Response to the Commercialization of American Media Before the Media Institute,” (May 25), (accessed November 30, 2005), [available at http://hraunfoss.fcc.gov/edocs_public/attachmatch/DOC-258962A1.doc].
BrodieMollyanne, FoehrUrsula, RideoutVicky, BaerNeal, MillerCarolyn, FlournoyRebecca, and AltmanDrew (2001), “Communicating Health Information Through the Entertainment Media,”Health Affairs, 20 (1), 192–99.
5.
WireBusiness (2005), “Court TV Offers the Prescription for Great ROI: The Network Joins Exhibitors at the Pharmaceutical Marketing Congress in Philadelphia September 12–14,” (June), (accessed November 19, 2005), [available at http://www.freedomcrowsnest.org/forum/viewtopic.php?t=12341].
Engle, Mary K., on behalf of the Federal Trade Commission (2005), FTC Letter to Gary Ruskin, (February 10), (accessed November 30, 2006), [available at http://www.commercialalert.org/FTCletter2.10.05.pdf].
FDA (2004), “Guidance for Industry: Help-Seeking and Other Disease Awareness Communications by or on Behalf of Drug and Device Firms,” (accessed September 10, 2006), [available at http://www.fda.gov/CDER/GUIDANCE/6019dft.pdf].
FontanarosaPhil, DrummondRennie, and DeAngelisCatherine (2003), “The Need for Regulation of Dietary Supplements: Lessons from Ephedra,”Journal of the American Medical Association, 289 (12), 1568–70.
FriedmanWayne (2004), “Placement Bonanza Remains Elusive; Advertisers, Programmers Continue to Test the Waters, but Big Deals and Big Payoffs Are Slow to Materialize,”Television Week, (October), (accessed November 25, 2005), [available at http://www.findarticles.com/p/articles/mi_go2037/is_200410/ai_n6662198].
17.
Ftc (2002), “Prepared Statement of the Federal Trade Commission, J. Howard Beales III, Director, Bureau of Consumer Protection, Before the Committee on Governmental Affairs Subcommittee on Oversight of Government Management, Restructuring and the District of Columbia United States Senate,” (accessed September 1, 2006), [available at http://www.ftc.gov/os/2002/10/dietary_testimony.htm].
GahartMartin T., LouiseM. Duhamel, DievlerAnne, and PriceRoseanne (2003), “Examining the FDA's Oversight of Direct-to-Consumer Advertising,” Health Affairs Web Exclusive, (February), 120–23, (accessed November 20, 2005), [available at http://content.healthaffairs.org/cgi/reprint/hlthaff.w3.120v1].
21.
HamiltonDavid P. (2002), “Celebrities Help ‘Educate’ Public on New Drugs,”The Wall Street Journal, (April 21), B1.
22.
The Henry J. Kaiser Family Foundation (2003), “Impact of Direct-to-Consumer Advertising on Prescription Drug Spending,” (June), (accessed November 20, 2005), [available at http://www.kff.org/rxdrugs/6084-index.cfm].
23.
HolmerAlan F. (2000), “Direct-to-Consumer Advertising: Strengthening Our Health Care System,”New England Journal of Medicine, 346 (7), 526–28.
KravitzRichard, EpsteinRonald, FeldmanMitchell, FranzCarol, AzariRahman, WilkesMichael, HintonLadson, and FranksPeter (2005), “Influence of Patients’ Requests for Direct-to-Consumer Advertised Antidepressants: A Randomized Controlled Trial,”Journal of the American Medical Association, 293 (16), 1995–2002.
27.
LylesAlan (2002), “Direct Marketing of Pharmaceuticals to Consumers,”Annual Review of Public Health, 23, 73–91.
28.
MekemsonCurtis, and GlantzStanton (2002), “How the Tobacco Industry Built Its Relationship with Hollywood,”Tobacco Control, 11 (March), 81–91.
PhRMA (2004), “Pharmaceutical Marketing and Promotion Questions and Answers: Tough Questions, Straight Answers,” (Fall), (accessed November 18, 2005), [available at http://www.phrma.org/files/Tough_Questions.pdf].
35.
PittsPeter J. (2004), “Turning Point or Tipping Point: New FDA Draft Guidance and the Future of DTC Advertising,” Health Affairs Web Exclusive, 259–261, (accessed November 18, 2005), [available at http://content.healthaffairs.org/cgi/reprint/hlthaff.w4.259v1].
36.
PQMedia (2005), “Product Placement Spending in Media 2005: Executive Summary,” (March), (accessed November 25, 2005), [available at http://www.pqmedia.com/ppsm2005-es.pdf].
37.
RobinsonAndrew R., KirstenB. Hohmann, JulieI. Rifkin, ToppDaniel, ChristineM. Gilroy, JeffreyA. Pickard, and RobertJ. Anderson (2004), “Direct-to-Consumer Pharmaceutical Advertising: Physician and Public Opinion and Potential Effects on the Physician-Patient Relationship,”Archives of Internal Medicine, 164 (4), 427–32.
38.
RussellCristel A. (2002), “Investigating the Effectiveness of Product Placements in Television Shows: The Role of Modality and Plot Connection Congruence on Brand Memory and Attitude,”Journal of Consumer Research, 29 (3), 306–318.
39.
RussellCristel A., and SternBarbara (2006), “Consumers, Characters, and Products,”Journal of Advertising, 35 (1), 7–12.
40.
SargentJames, TickleJennifer, BeachMichael, DaltonMadeline, AhrensBridget, and HeathertonTodd (2001), “Brand Appearances in Contemporary Cinema Films and Contribution to Global Marketing of Cigarettes,”The Lancet, 357 (9249), 29–32.
WilkesMichael S., RobertA. Bell, and RichardL. Kravitz (2000), “Direct-to-Consumer Prescription Drug Advertising: Trends, Impact and Implications,”Health Affairs, 19 (2), 110–28.
43.
WoloshinSteve, LisaM. Schwartz, TremmelJennifer, and Gilbert WelchH. (2001), “Direct-to-Consumer Advertisements for Prescription Drugs: What Are Americans Being Sold?”The Lancet, 358 (9288), 1141–46.
